Application of machine learning methods to guide patient management by predicting the risk of malignancy of Bethesda III-V thyroid nodules.

cytopathological features machine learning predictive model risk of malignancy thyroid cancer thyroid nodules ultrasonographic features

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
02 Mar 2023
Historique:
received: 15 09 2022
revised: 27 01 2023
accepted: 30 01 2023
pubmed: 18 2 2023
medline: 7 3 2023
entrez: 17 2 2023
Statut: ppublish

Résumé

Indeterminate thyroid nodules (ITN) are common and often lead to (sometimes unnecessary) diagnostic surgery. We aimed to evaluate the performance of two machine learning methods (ML), based on routinely available features to predict the risk of malignancy (RM) of ITN. Multi-centric diagnostic retrospective cohort study conducted between 2010 and 2020. Adult patients who underwent surgery for at least one Bethesda III-V thyroid nodule (TN) with fully available medical records were included. Of the 7917 records reviewed, eligibility criteria were met in 1288 patients with 1335 TN. Patients were divided into training (940 TN) and validation cohort (395 TN). The diagnostic performance of a multivariate logistic regression model (LR) and its nomogram, and a random forest model (RF) in predicting the nature and RM of a TN were evaluated. All available clinical, biological, ultrasound, and cytological data of the patients were collected and used to construct the two algorithms. There were 253 (19%), 693 (52%), and 389 (29%) TN classified as Bethesda III, IV, and V, respectively, with an overall RM of 35%. Both cohorts were well-balanced for baseline characteristics. Both models were validated on the validation cohort, with performances in terms of specificity, sensitivity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve of 90%, 57.3%, 73.4%, 81.4%, 84% (CI95%: 78.5%-89.5%) for the LR model, and 87.6%, 54.7%, 68.1%, 80%, 82.6% (CI95%: 77.4%-87.9%) for the RF model, respectively. Our ML models performed well in predicting the nature of Bethesda III-V TN. In addition, our freely available online nomogram helped to refine the RM, identifying low-risk TN that may benefit from surveillance in up to a third of ITN, and thus may reduce the number of unnecessary surgeries.

Identifiants

pubmed: 36799885
pii: 7044677
doi: 10.1093/ejendo/lvad017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of (ESE) European Society of Endocrinology.

Déclaration de conflit d'intérêts

Conflicts of interest: The authors declare that they have no conflicts of interest.

Auteurs

Grégoire D'Andréa (G)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Jocelyn Gal (J)

Department of Statistics, Centre Antoine Lacassagne, Nice 06103, France.

Loïc Mandine (L)

Department of Statistics, Centre Antoine Lacassagne, Nice 06103, France.

Olivier Dassonville (O)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Clair Vandersteen (C)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Nicolas Guevara (N)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Laurent Castillo (L)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Gilles Poissonnet (G)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Dorian Culié (D)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Roxane Elaldi (R)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Jérôme Sarini (J)

Otorhinolaryngology and Head and Neck Surgery Department, University Cancer Institute of Toulouse-Oncopole, Toulouse 31400, France.

Anne Decotte (A)

Otorhinolaryngology and Head and Neck Surgery Department, Toulouse University Hospital, Hôpital Larrey, Toulouse 31400, France.

Claire Renaud (C)

Thoracic Surgery Department, Toulouse University Hospital, Hôpital Larrey, Toulouse 31400, France.

Sébastien Vergez (S)

Otorhinolaryngology and Head and Neck Surgery Department, University Cancer Institute of Toulouse-Oncopole, Toulouse 31400, France.
Otorhinolaryngology and Head and Neck Surgery Department, Toulouse University Hospital, Hôpital Larrey, Toulouse 31400, France.

Renaud Schiappa (R)

Department of Statistics, Centre Antoine Lacassagne, Nice 06103, France.

Emmanuel Chamorey (E)

Department of Statistics, Centre Antoine Lacassagne, Nice 06103, France.

Yann Château (Y)

Department of Statistics, Centre Antoine Lacassagne, Nice 06103, France.

Alexandre Bozec (A)

Otorhinolaryngology and Head and Neck Surgery Department, Institut Universitaire de la Face et du Cou, GHS Nice University Hospital-Antoine Lacassagne Centre, Côte d'Azur University, Nice 06103, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH